98%
921
2 minutes
20
Background: Most Prostate Imaging-Reporting and Data System (PI-RADS) 3 lesions do not contain clinically significant prostate cancer (CSPCa; grade group ≥2). This study was aimed at identifying clinical and magnetic resonance imaging (MRI)-derived risk fac- tors that predict CSPCa in men with PI-RADS 3 lesions.
Methods: This study analyzed the detection of CSPCa in men who underwent MRI-targeted biopsy for PI-RADS 3 lesions. Multivariable logistic regression models with goodness-of-fit testing were used to identify variables associated with CSPCa. Receiver operating curves and decision curve analyses were used to estimate the clinical utility of a predictive model.
Results: Of the 1784 men reviewed, 1537 were included in the training cohort, and 247 were included in the validation cohort. The 309 men with CSPCa (17.3%) were older, had a higher prostate-specific antigen (PSA) density, and had a greater likelihood of an anteriorly located lesion than men without CSPCa (p < .01). Multivariable analysis revealed that PSA density (odds ratio [OR], 1.36; 95% confidence interval [CI], 1.05-1.85; p < .01), age (OR, 1.05; 95% CI, 1.02-1.07; p < .01), and a biopsy-naive status (OR, 1.83; 95% CI, 1.38-2.44) were independently associated with CSPCa. A prior negative biopsy was negatively associated (OR, 0.35; 95% CI, 0.24-0.50; p < .01). The application of the model to the validation cohort resulted in an area under the curve of 0.78. A predicted risk threshold of 12% could have prevented 25% of biopsies while detecting almost 95% of CSPCas with a sensitivity of 94% and a specificity of 34%.
Conclusions: For PI-RADS 3 lesions, an elevated PSA density, older age, and a biopsy-naive status were associated with CSPCa, whereas a prior negative biopsy was negatively associated. A predictive model could prevent PI-RADS 3 biopsies while missing few CSPCas.
Lay Summary: Among men with an equivocal lesion (Prostate Imaging-Reporting and Data System 3) on multiparametric magnetic resonance imaging (mpMRI), those who are older, those who have a higher prostate-specific antigen density, and those who have never had a biopsy before are at higher risk for having clinically significant prostate cancer (CSPCa) on subsequent biopsy. However, men with at least one negative biopsy have a lower risk of CSPCa. A new predictive model can greatly reduce the need to biopsy equivocal lesions noted on mpMRI while missing only a few cases of CSPCa.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/cncr.34355 | DOI Listing |
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, University of California Irvine, Irvine, CA, USA.
Pol J Radiol
July 2025
University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Türkiye.
Purpose: The purpose of this study was to determine the effectiveness of ADC histogram analysis in diagnosing and determining the aggressiveness of peripheral zone (PZ) prostate cancer, and to reveal the relationship between Gleason and PI-RADS scores.Material and method: 61 patients who underwent standard 12-core and cognitive prostate biopsy and multiparametric prostate magnetic resonance imaging before biopsy were included in the study. According to the pathology results, patients were classified as either having clinically significant cancer with malignancy ( = 35) or as clinically insignificant - benign ( = 26).
View Article and Find Full Text PDFInvestig Clin Urol
September 2025
Department of Urology, Pusan National University School of Medicine, Yangsan, Korea.
Purpose: This study evaluated inter-/intra-reader agreement with the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 to improve the detection rate of prostate cancer.
Materials And Methods: We enrolled 210 patients who underwent multiparametric magnetic resonance imaging (mpMRI) for clinically suspected or diagnosed prostate cancer.
Maedica (Bucur)
June 2025
Department of Urology, "Prof. Dr. Th. Burghele" Clinical Hospital, Bucharest, Romania.
Objectives: This study aimed to evaluate the clinical utility of the SelectMDx urinary biomarker test in men with PI-RADS 3 lesions identified through multiparametric magnetic resonance imaging (mpMRI), a subgroup in which prostate cancer diagnosis remains uncertain. The primary objective was to assess whether SelectMDx can improve risk stratification for clinically significant prostate cancer and thereby reduce unnecessary prostate biopsies.
Materials And Methods: A prospective cohort of 40 patients with serum prostate-specific antigen (PSA) levels ≥3 ng/mL and PI-RADS ≥ 3 lesions on mpMRI was analyzed.
J Clin Med
August 2025
Department of Paediatric Radiology, Medical University of Bialystok, 17 Waszyngtona St., 15-274 Bialystok, Poland.
Accurate histopathological grading of prostate cancer at the time of biopsy is essential for guiding treatment decisions and minimizing the risks of both overtreatment and undertreatment. A key challenge in prostate cancer diagnostics is the phenomenon of upgrading, wherein the cancer appears more aggressive in the radical prostatectomy specimen than initially indicated by biopsy. Such discrepancies can compromise therapeutic planning.
View Article and Find Full Text PDF